No One-Trick Pony in Oncology, Merck’s Cancer Footprint Is Expanding

Why It Matters

Diversifying its oncology assets reduces Merck’s reliance on Keytruda’s patent cliffs and positions the company for sustained growth in high‑margin cancer markets.

Key Takeaways

• Merck spent $700M on Curon bispecific candidate.
• Acquired Harpoon Therapeutics for $680M T‑cell engagers.
• ADC sac‑TMT in 16 late‑stage trials, growth driver.
• KRAS inhibitor calderasib entered phase 3 NSCLC trial.
• Keytruda plus Padcev reduced death risk by 50%.

Pulse Analysis

Merck’s oncology strategy is undergoing a decisive shift as the company confronts the looming patent expirations of Keytruda, its multi‑billion‑dollar PD‑1 blockbuster. 38 billion into external assets in 2024, acquiring Harpoon Therapeutics for $680 million and licensing a bispecific program from Curon Biopharmaceutical for $700 million. These deals give Merck immediate entry into T‑cell engager technology and bispecific antibodies, platforms that have shown rapid clinical uptake and promise to complement the existing immunotherapy franchise. The moves also signal Merck’s intent to compete with rivals such as Bristol Myers and Roche in the fast‑growing bispecific space.

The expanded pipeline follows a three‑pronged approach. In the immune‑modulating arena, the Harpoon‑derived candidate gocatamig is being tested in mid‑stage lung cancer trials and co‑developed with Daiichi Sankyo. Early data suggest gocatamig may synergize with PD‑1 blockade, a hypothesis Merck plans to test in upcoming combination cohorts. Tissue‑targeting efforts center on the antibody‑drug conjugate sac‑TMT, now enrolled in 16 late‑stage studies across breast, lung and women’s cancers, and projected as a 2027 growth driver. On the tumor‑intrinsic front, Merck’s KRAS G12C inhibitor calderasib has entered a phase 3 trial for non‑small‑cell lung cancer, extending the company’s reach into previously “undruggable” oncogenes.

Together, these assets enable Merck to pair novel agents with Keytruda, accelerating entry into earlier lines of therapy and creating combination regimens that could boost overall survival. For investors, the diversification reduces exposure to a single product’s lifecycle risk and aligns the company with the broader industry trend toward precision oncology and combination immunotherapy. If sac‑TMT and calderasib achieve their projected milestones, Merck could generate multiple new blockbuster revenues, reinforcing its position as a leading global oncology innovator. Analysts project that successful commercialization could lift Merck’s oncology earnings multiple by double‑digits within the next three years.